Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression

CTNNB1 mutations activating ß‐catenin are frequent somatic events in hepatocellular carcinoma (HCC) and adenoma (HCA), particularly associated with a risk of malignant transformation. We aimed to understand the relationship between CTNNB1 mutation types, tumor phenotype, and level of ß‐catenin activation in malignant transformation. To this purpose, CTNNB1 mutation spectrum was analyzed in 220 HCAs, 373 HCCs, and 17 borderline HCA/HCC lesions. ß‐catenin activation level was assessed in tumors by quantitative reverse‐transcriptase polymerase chain reaction and immunohistochemistry (IHC), in cellulo by TOP‐Flash assay. Overall, ß‐catenin activity was higher in malignant mutated tumors, compared to adenomas, and this was related to a different spectrum of CTNNB1 mutations in HCCs and HCAs. In benign tumors, we defined three levels of ß‐catenin activation related to specific mutations: (1) S45, K335, and N387 mutations led to weak activation; (2) T41 mutations were related to moderate activity; and (3) highly active mutations included exon 3 deletions and amino acid substitutions within the ß‐TRCP binding site (D32‐S37). Accordingly, in vitro, K335I and N387K mutants showed a lower activity than S33C. Tumors with highly active mutations demonstrated strong/homogeneous glutamine synthase (GS) staining and were associated with malignancy. In contrast, weak mutants demonstrated heterogeneous pattern of GS staining and were more frequent in HCAs except for the S45 mutants identified similarly in 20% of mutated HCAs and HCCs; however, in most of the HCCs, the weak S45 mutant alleles were duplicated, resulting in a final high ß‐catenin activity. Conclusion: High ß‐catenin activity driven by specific CTNNB1 mutations and S45 allele duplication is associated with malignant transformation. Consequently, HCAs with S45 and all high/moderate mutants should be identified with precise IHC criteria or mutation screening. (Hepatology 2016;64:2047‐2061)

[1]  J. Zucman‐Rossi,et al.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. , 2015, Gastroenterology.

[2]  L. Terracciano,et al.  Nrf2, but not β‐catenin, mutation represents an early event in rat hepatocarcinogenesis , 2015, Hepatology.

[3]  L. Qin,et al.  β-catenin mutation is correlated with a favorable prognosis in patients with hepatocellular carcinoma. , 2015, Molecular and clinical oncology.

[4]  Jessica Zucman-Rossi,et al.  Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.

[5]  A. Zell,et al.  Dysregulated serum response factor triggers formation of hepatocellular carcinoma , 2015, Hepatology.

[6]  J. Zucman‐Rossi,et al.  Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis , 2014, Hepatology.

[7]  Jessica Zucman-Rossi,et al.  Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. , 2014, Cancer cell.

[8]  J. Calderaro,et al.  High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions , 2013, Nature Communications.

[9]  S. Imbeaud,et al.  A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. , 2013, Gastroenterology.

[10]  Jessica Zucman-Rossi,et al.  Hepatocellular benign tumors-from molecular classification to personalized clinical care. , 2013, Gastroenterology.

[11]  S. Imbeaud,et al.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma , 2012, Nature Genetics.

[12]  J. Zucman‐Rossi,et al.  Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas , 2011, The Journal of experimental medicine.

[13]  E. Kuipers,et al.  Colorectal Cancers Choosing Sides , 2011 .

[14]  Y. Jeng,et al.  Role of p53 and β-catenin Mutations in Conjunction with CK19 Expression on Early Tumor Recurrence and Prognosis of Hepatocellular Carcinoma , 2011, Journal of Gastrointestinal Surgery.

[15]  C. Dai,et al.  Accelerated liver regeneration and hepatocarcinogenesis in mice overexpressing serine‐45 mutant β‐catenin , 2010, Hepatology.

[16]  B. Cieply,et al.  Unique phenotype of hepatocellular cancers with exon‐3 mutations in beta‐catenin gene , 2009, Hepatology.

[17]  S. Imbeaud,et al.  Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours , 2009, Nature.

[18]  Yu Wei,et al.  Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. , 2008, Cancer cell.

[19]  T. Lister,et al.  Segmental uniparental disomy is a commonly acquired genetic event in relapsed acute myeloid leukemia. , 2008, Blood.

[20]  Rolf Gebhardt,et al.  Correlation between β-catenin mutations and expression of Wnt-signaling target genes in hepatocellular carcinoma , 2008, Molecular Cancer.

[21]  Cristel G. Thomas,et al.  Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry , 2007, Hepatology.

[22]  C. Elie,et al.  Cholestasis is a marker for hepatocellular carcinomas displaying β‐catenin mutations , 2007, The Journal of pathology.

[23]  S. Boyault,et al.  Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas , 2007, Oncogene.

[24]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[25]  J. Zucman‐Rossi,et al.  Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC , 2006, Hepatology.

[26]  T. A. Lister,et al.  Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. , 2005, Cancer research.

[27]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[28]  K. Kinzler,et al.  Phosphorylation of β-Catenin at S33, S37, or T41 Can Occur in the Absence of Phosphorylation at T45 in Colon Cancer Cells , 2003 .

[29]  J. Zucman‐Rossi,et al.  Bi-allelic inactivation of TCF1 in hepatic adenomas , 2002, Nature Genetics.

[30]  R. Fodde,et al.  The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the beta-catenin signaling cascade. , 2002, Human molecular genetics.

[31]  Matthias Mann,et al.  Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. , 2002, Genes & development.

[32]  Xi He,et al.  Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism , 2002, Cell.

[33]  A. Buchmann,et al.  Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of β-catenin-mutated mouse liver tumors , 2001, Oncogene.

[34]  G. Thomas,et al.  Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. , 2001, Gastroenterology.

[35]  I. Lubensky,et al.  Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. , 2000, Cancer research.

[36]  M. Evans,et al.  Overexpression of beta-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. , 2000, Molecular biology of the cell.

[37]  Y. Jeng,et al.  Beta-catenin mutations are associated with a subset of low-stage hepatocellular carcinoma negative for hepatitis B virus and with favorable prognosis. , 2000, The American journal of pathology.

[38]  Sabine Tejpar,et al.  Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor) , 1999, Oncogene.

[39]  Ian Tomlinson,et al.  The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis , 1999, Nature Medicine.

[40]  W. Marston Linehan,et al.  Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas , 1998, Nature Genetics.

[41]  M. Buendia,et al.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[42]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[43]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Hope.  A Simplified Monte Carlo Significance Test Procedure , 1968 .

[45]  J. Tran van Nhieu,et al.  GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. , 2012, Journal of hepatology.

[46]  Xi He,et al.  Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. , 2002, Cell.

[47]  Jan Kitajewski,et al.  New targets of β-catenin signaling in the liver are involved in the glutamine metabolism , 2002, Oncogene.